AndroGel for Male Hypogonadism

What Is Male Hypogonadism and How Is It Diagnosed?

Male hypogonadism is a clinical syndrome where the testes produce insufficient testosterone, causing symptoms that range from low libido and chronic fatigue to loss of muscle mass and depressed mood. Diagnosis requires both biochemical confirmation and symptomatic presentation, not lab values alone.

The Endocrine Society's 2018 clinical practice guideline defines the diagnostic threshold as a total testosterone level below 300 ng/dL, measured on at least two separate morning blood draws (before 10:00 AM), because testosterone follows a circadian rhythm and peaks in early morning hours [1]. The CDC-harmonized LC-MS/MS cutoff used in population studies is slightly lower at 264 ng/dL. Both values serve as reasonable clinical thresholds depending on the assay platform your lab uses.

Free testosterone measurement adds diagnostic precision when total T falls in a borderline range (250 to 350 ng/dL), especially in men with obesity or altered sex hormone-binding globulin (SHBG) levels. Conditions that raise SHBG, including aging, liver disease, and hyperthyroidism, can make total T appear falsely normal while free (bioavailable) testosterone is genuinely low.

Prevalence data from the Baltimore Longitudinal Study of Aging estimated that roughly 20% of men over age 60 to 30% over age 70, and 50% over age 80 have total testosterone levels below 325 ng/dL [2]. The condition is not exclusive to older men. Secondary causes in younger males include pituitary tumors, opioid use, Klinefelter syndrome, and prior anabolic steroid abuse.

How AndroGel Works as Testosterone Replacement

AndroGel delivers exogenous testosterone through the skin into the bloodstream, bypassing first-pass liver metabolism that limits oral testosterone formulations. The gel dries within minutes and testosterone absorbs steadily over several hours, producing relatively stable serum levels when applied at the same time each day.

The FDA first approved AndroGel 1% in February 2000 for testosterone replacement in adult males with conditions associated with a deficiency or absence of endogenous testosterone [3]. AndroGel 1.62% followed in 2011, offering a smaller application volume with equivalent testosterone delivery. Both formulations are classified as Schedule III controlled substances under the Anabolic Steroids Control Act.

A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism demonstrated that AndroGel 1% at the 50 mg daily dose raised mean serum testosterone from a baseline of approximately 237 ng/dL to 570 ng/dL within 30 days, with 87% of subjects achieving levels in the 300 to 1 to 000 ng/dL normal range [4]. Steady-state concentrations are typically reached by day 14 of consistent use.

The testosterone absorbed from the gel undergoes the same metabolism as endogenous testosterone. It converts to dihydrotestosterone (DHT) via 5-alpha-reductase and to estradiol via aromatase, which means the full spectrum of androgen and estrogen-mediated effects occurs, including both therapeutic benefits and potential side effects.

The T-Trials: Largest Evidence Base for Topical Testosterone in Older Men

The Testosterone Trials (TRT Trials or "T-Trials") represent the most rigorous body of evidence for topical testosterone gel in older hypogonadal men. This coordinated set of seven placebo-controlled trials enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism.

Published in the New England Journal of Medicine in 2016, the initial three trials (Sexual Function, Physical Function, and Vitality) showed that one year of daily testosterone gel application raised mean serum testosterone from 232 ng/dL to 565 ng/dL [5]. Sexual function improved significantly: the Psychosexual Daily Questionnaire sexual desire score increased by 0.62 points in the testosterone group vs. 0.08 points in the placebo group (P<0.001). Sexual activity frequency also improved. Physical function showed a modest but statistically significant benefit in the 6-minute walk test, though the magnitude (approximately 6 meters) was below the minimally clinically important difference. Vitality scores did not differ significantly between groups.

The cardiovascular sub-study (TRAVERSE), published separately, enrolled 5,246 men aged 45 to 80 with hypogonadism plus established or high-risk cardiovascular disease. At a median follow-up of 33 months, testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo (7.0% vs. 7.3%; HR 0.96 to 95% CI 0.78 to 1.17) [6]. This trial, published in NEJM in 2023, largely resolved a decade of uncertainty about cardiovascular safety of TRT.

The bone density sub-study demonstrated that testosterone gel increased volumetric bone mineral density of the spine by 7.5% over 12 months compared to placebo, measured by quantitative CT [7]. This effect was concentrated in trabecular bone, the compartment most susceptible to age-related loss.

AndroGel Dosing: Starting, Titrating, and Monitoring

Correct dosing of AndroGel depends on the formulation. The protocols differ between the 1% and 1.62% concentrations, and underdosing is one of the most common reasons patients report "testosterone gel doesn't work."

AndroGel 1% dosing: Start at 50 mg (two 25 mg packets or four pump actuations) applied once daily. If serum testosterone remains below 300 ng/dL after 14 to 28 days, increase to 75 mg daily. The maximum recommended dose is 100 mg daily [3].

AndroGel 1.62% dosing: Start at 40.5 mg (two pump actuations) applied once daily. Dose can be adjusted in 20.25 mg increments based on serum testosterone measured 14 days after initiation or dose change. The dose range spans 20.25 mg to 81 mg daily [3].

The Endocrine Society guideline recommends measuring serum testosterone 2 to 4 weeks after starting therapy or changing dose, with the sample drawn 2 to 8 hours after gel application [1]. Target the mid-normal range (450 to 600 ng/dL). Levels above 1 to 000 ng/dL or below 300 ng/dL require dose adjustment.

Application technique matters. The gel should be applied to clean, dry skin on the shoulders, upper arms, or abdomen. Patients should avoid showering, swimming, or applying sunscreen to the treated area for at least 2 hours (5 hours for AndroGel 1.62%) after application. Rotating application sites reduces local skin irritation.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has stated: "The most frequent reason topical testosterone fails is inconsistent application or premature washoff. Patients need to understand this is a daily medication, not something you use as needed."

Monitoring labs at baseline and at 3, 6, and 12 months should include total testosterone, hematocrit/hemoglobin, PSA (for men over 40), fasting lipid panel, and liver function tests. Annual DEXA scans may be warranted in men with baseline osteopenia.

Comparing AndroGel to Other TRT Formulations

AndroGel is one of several FDA-approved testosterone delivery systems. The choice between formulations depends on patient preference, insurance coverage, lifestyle factors, and tolerance of specific side effects.

Testosterone cypionate injections (100 to 200 mg every 1 to 2 weeks) produce higher peak-to-trough fluctuations than daily gel, which some men experience as mood swings or energy crashes in the days before their next injection. A 2017 meta-analysis in Andrologia found that gels and injections produced equivalent improvements in sexual function, lean body mass, and bone density, though patient-reported satisfaction scores were comparable across formulations [8]. Cost is the principal difference: generic testosterone cypionate costs $30 to $60 per month, while brand-name AndroGel can exceed $500 monthly without insurance.

Testosterone patches (Androderm) provide similar steady-state pharmacokinetics to gels but cause application-site skin reactions in 30% to 60% of users, significantly higher than the 5% to 10% rate seen with AndroGel [3].

Nasal testosterone (Natesto) and oral testosterone undecanoate (Jatenzo, Tlando, Kyzatrex) offer alternatives for men concerned about skin transfer risk but require multiple daily doses (Natesto: three times daily; oral: twice daily with food containing at least 30 g fat).

Subcutaneous testosterone pellets (Testopel) are implanted every 3 to 6 months and eliminate daily adherence concerns, but pellet extrusion occurs in roughly 5% to 12% of insertions and dose adjustment requires waiting until the next implant cycle.

For men who prefer daily self-administration without injection anxiety and who can reliably apply gel and avoid skin contact with partners, AndroGel remains the most prescribed topical TRT in the United States.

Side Effects and Safety Considerations

The side effect profile of AndroGel mirrors that of testosterone replacement in general, with one formulation-specific concern: secondary exposure through skin-to-skin transfer.

Erythrocytosis (elevated hematocrit) is the most common lab abnormality during TRT. The Endocrine Society guideline recommends holding therapy if hematocrit exceeds 54% and restarting at a lower dose after therapeutic phlebotomy [1]. In the T-Trials, hematocrit rose above 54% in approximately 4% of testosterone-treated men vs. 0.5% of placebo [5].

Acne and oily skin occur in 5% to 8% of gel users, typically within the first 3 months. Most cases are mild and respond to topical treatment.

Fertility suppression is expected during exogenous testosterone use. Testosterone replacement suppresses gonadotropins (LH and FSH), which in turn suppresses spermatogenesis. The American Urological Association explicitly warns against prescribing any exogenous testosterone to men trying to conceive [9]. Recovery of spermatogenesis after TRT discontinuation typically takes 6 to 12 months, though in some cases it may take longer or may not fully recover.

Secondary exposure carries a black box warning on all topical testosterone products. Testosterone transferred through skin contact can cause virilization in women (voice deepening, hirsutism) and precocious puberty in children. The FDA mandates that AndroGel labeling instruct patients to cover the application site with clothing after drying and wash hands immediately after application [3].

Cardiovascular risk, once the dominant safety concern, was addressed by the TRAVERSE trial. At a median 33-month follow-up, testosterone gel did not increase major adverse cardiovascular events compared to placebo (hazard ratio 0.96; 95% CI 0.78 to 1.17) [6]. The FDA previously added a general warning about cardiovascular risk to all testosterone products in 2015, but the TRAVERSE data prompted a 2024 FDA label update acknowledging the reassuring cardiovascular findings.

Sleep apnea may worsen during TRT. Screen patients with symptoms of obstructive sleep apnea at baseline and during follow-up. This does not mean TRT causes sleep apnea, but untreated severe sleep apnea is a relative contraindication to starting therapy.

Insurance Coverage and Cost of AndroGel

Brand-name AndroGel is one of the more expensive TRT options, with retail pricing around $500 to $700 per month for a 30-day supply without insurance. The availability of generic testosterone gel 1% since 2015 has improved affordability considerably, with generic versions costing $50 to $150 per month depending on pharmacy and dose.

Most commercial insurance plans and Medicare Part D cover testosterone gel for men with a documented diagnosis of hypogonadism (ICD-10 code E29.1), but many require prior authorization. Typical PA criteria include two documented morning total testosterone levels below 300 ng/dL, presence of clinical symptoms, and no contraindications such as untreated prostate cancer or male breast cancer.

Some insurers mandate a trial of generic testosterone cypionate injections before approving brand-name AndroGel or AndroGel 1.62%, which remains patent-protected. This step therapy requirement has become increasingly common since 2020.

Manufacturer savings cards (from AbbVie) can reduce brand-name AndroGel copays to $0 to $75 per month for commercially insured patients. These cards do not apply to government insurance programs (Medicare, Medicaid, Tricare, VA).

For uninsured patients, generic testosterone gel 1% purchased through GoodRx or similar discount programs typically costs $80 to $120 per month. Testosterone cypionate vials remain the most affordable option at $30 to $60 monthly.

Who Should Not Use AndroGel

The Endocrine Society guideline lists absolute contraindications: breast cancer, known or suspected prostate cancer, unevaluated prostate nodules or PSA above 4 ng/mL (or above 3 ng/mL in high-risk men), hematocrit above 50% at baseline, untreated severe obstructive sleep apnea, uncontrolled heart failure (NYHA class III or IV), desire for fertility in the near term, and a history of thrombophilia-related venous thromboembolism [1].

Relative contraindications include severe lower urinary tract symptoms (IPSS score above 19), poorly controlled bipolar disorder, and a PSA velocity exceeding 0.4 ng/mL per year. These situations do not prohibit TRT outright but require specialist consultation and closer monitoring.

Men living with female partners or children should evaluate whether the secondary transfer risk is manageable given their household circumstances. If transfer risk is the primary concern, injectable or implantable testosterone formulations eliminate it entirely.